14.11.2012 07:30:00

ORPEA: Growth Accelerates to 17.6% in Q3 2012, with Sales Totalling €366.4 Million

Regulatory News:

ORPEA (Paris:ORP), leading European player in Long-Term Care (nursing homes), Post-Acute Care and Psychiatric Care, today announced its revenues for the third quarter of 2012 to 30th September.

                 

In €m
IFRS

Quarterly 9-months
Q3 2012       Q3 2011       Var. 2012       2011       Var.
France 307.2       274.3       +12.0% 909.1       800.0       +13.6%
% of total sales 84%       88%         86%       88%        
International 59.2 37.4 +58.4% 142.1 105.9 +34.2%
% of total sales 16% 12% 14% 12%
Belgium 34.7 17.4 71.1 51.1
Spain 12.1 7.9 36.8 23.0
Italy 8.7 8.0 22.9 20.0
Switzerland 3.7       4.0         11.3       11.8        
Total sales 366.4 311.7 +17.6% 1 051.2 905.9 +16.0%

Organic growth1

                +7.8%                 +8.3%
 

Yves Le Masne, CEO of ORPEA, comments: "The growth momentum achieved by ORPEA since the beginning of the year has continued and even accelerated during the third quarter. Sales advanced by 17.6% on the back of further brisk organic growth (7.8%) and a strong increase in international markets (58.4%) thanks in particular to the successful integration of Artevida in Spain and of Medibelge in Belgium.

Organic growth, which reached 8.3% over the first nine months of the year, was again underpinned by:

  • a high occupancy rate at mature facilities in all the European markets;
  • the ramp-up of facilities opened recently in strategic locations and offering a high standard of quality;
  • the opening of close to 900 new beds during the quarter, representing around ten facilities, lifting the total number opened since the beginning of 2012 to 1,900.

Through these accomplishments, ORPEA continues its commitment to the local economy, creating around 1,000 jobs since the beginning of the year.

With sales growth running at 16.0% over the first nine months of the year, ORPEA is confident in its ability to meet its full-year sales target of €1,425 million in 2012, together with improvement in its margins and cash flow.

Looking ahead to 2013 and subsequent years, ORPEA is very confident that it will be able to achieve solid growth in its sales and margins by tapping its pipeline of close to 8,000 beds and structural factors, including the ageing of the population.”

Next press release: revenues for 2012 full-year, 13th February 2013, before market

About ORPEA (www.orpea-corp.com)

Listed on Euronext Paris since April 2002 and a member of the Deferred Settlement Service, the ORPEA group is the leading European player in the Long-Term Care and Post-Acute Care sectors.

At 31 July 2012, the Group had a unique European network of healthcare facilities with 38,348 beds (33,317 of them operational) at over 410 sites, including:

  • 28,819 beds in France: 25,340 operational (including 2,296 being renovated) + 3,479 under construction, at 333 facilities,
  • 9,529 beds in Europe (Spain, Belgium, Italy and Switzerland): 7,977 operational (including 754 being renovated) + 1,552 under construction, at 77 facilities.

Listed on Euronext Paris Compartment of NYSE Euronext

Member of the CAC Mid 60 and SBF 120 indices - Member of the SRD

ISIN: FR0000184798 - Reuters: ORP.PA - Bloomberg: ORP FP

1 Organic growth is the result of the following factors: creations of new facilities, extensions to or restructuring of existing facilities, as well as changes in occupancy rates and daily rates. Organic growth is analysed facility by facility. Growth incorporates improvements in sales compared to the previous equivalent period, for recently-acquired facilities.

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Nachrichten zu OrpeaAct.mehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu OrpeaAct.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Indizes in diesem Artikel

CAC MID 60 12 844,86 0,01%
SBF 120 5 448,33 0,01%